The company and its collaborators previously published a study linking saliva concentrations of multiple microRNAs with concussion duration and symptoms in children.
Washington University researchers and a team including scientists from Eli Lilly independently identified a modified form of tau as a promising Alzheimer's marker.
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
The researchers found that levels of the marker, which has also been studied in diseases like MS and Alzheimer's, correlated with severity of traumatic brain injury.
